Marie M.
- Country
- Belgium
- Department
- Departement of Hematology
Research Overview
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)
Data & Insights
Has run more than one trial at 7 of 129 partner sites.
Specializations
Lymphoma Treatment Innovation
This investigator specializes in developing innovative treatments for B-cell lymphomas, with particular emphasis on Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Their research encompasses both newly diagnosed and relapsed/refractory cases.
- Novel therapeutic combinations for DLBCL
- Treatment strategies for high-risk lymphoma patients
- Advanced approaches for refractory cases
Targeted Therapies
The investigator focuses on evaluating novel targeted agents including tazemetostat, odronextamab, and zanubrutinib in combination with established treatment regimens. Their work explores immunotherapy approaches for various lymphoma subtypes.
- Immunotherapy combinations
- Antibody-based treatments
- Personalized medicine approaches
Specialized Lymphoma Types
Their research extends to multiple lymphoma subtypes, including Marginal Zone Lymphoma (MZL) and various B-cell malignancies. The investigator studies treatment optimization for different patient populations.
- B-cell lymphoma variants
- High-risk patient populations
- Rare lymphoma subtypes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.